AIM:To investigate the surgical treatment of patientswith intermediate-terminal pancreatic cancer.METHODS:A retrospective analysis was made of theclinical data of 163 patients with intermediate-terminalpancreatic cancer who were surgically treated betweenAugust 1994 and August 2003.RESULTS:A total of 149 patients underwent pallia-tive surgery.The mortality rate of those who underwentcholecystojejunostomy alone was 14.2%,the icterus orcholangitis recurrence rate was 61.9% with an averagesurvival period of 7.1 mo.The mortality rate for thosewho received hepatic duct-jejunostomy(HDJS)was 5.7%,the icterus or cholangitis recurrence rate was 6.8% withan average survival period of 7.1 mo.But 31.8% of thepatients developed duodenum obstruction within 6 moafter the surgery,six of seven patients with severe painwere given peri-abdominal aorta injection with absolutealcohol and their pain was alleviated.The other patientsunderwent percutaneous transhepatic cholangial drain-age(PTCD)and their icterus index returned to normallevel within 40 d with an average survival period of 7.5 mo.CONCLUSION:Roux-en-y HDJS combined withprophylactic gastrojejunostomy is recommended for pa-tients with intermediate-terminal pancreatic cancer,andbiliary prosthesis can partly relieve biliary obstruction ina short term. AIM: To investigate the surgical treatment of patients with intermediate-terminal pancreatic cancer. METHODS: A retrospective analysis was made of the clinical data of 163 patients with intermediate-terminal pancreatic cancer who were surgically treated between August 1994 and August 2003.RESULTS: A total of 149 patients underwent pallia-tive surgery. mortality rate of those who underwentcholecystojejunostomy alone was 14.2%, the icterus orcholangitis recurrence rate was 61.9% with an acquiredurival period of 7.1 mo. mortality rate for those who received hepatic duct-jejunostomy (HDJS) was 5.7% , the icterus or cholangitis recurrence rate was 6.8% withan average survival period of 7.1 mo.But 31.8% of thepatients developed duodenum obstruction within 6 moafter the surgery, six of seven patients with severe painwere given peri-abdominal aorta injection with absolute alcohol and their pain was alleviated.The other patientunderwent percutaneous transhepatic cholangial drain-age (PTCD) and their icte rus index returned to normal level within 40 d with an average survival period of 7.5 mo. CONCLUSION: Roux-en-y HDJS combined with prophylactic gastrojejunostomy is recommended for pa-tients with intermediate-terminal pancreatic cancer, and biliary prosthesis can partly relieve biliary obstruction ina short term.